LXRX Phase III sotagliflozin HCM data expected in Q1 2027
LXRX expects key Phase III sotagliflozin data in HCM in Q1 2027, with commercial preparations underway. For T1D, an FDA resubmission is planned for Q4 as regulatory progress continues.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.